14:59 Mon 21 Dec 2020
NetScientific PLC - PDS Announces Publication of Data by Mount Sinai
NetScientific plc
("NetScientific" or the "Company")
PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamuneâ-based COVID-19 Vaccine
Versamuneâ T-cell activating platform demonstrates breadth of
anti-SARS-CoV-2 immune responses in a COVID-19 vaccine
Dr.
"The first wave of COVID-19 vaccines focused on antibody generation. However, there is a growing body of literature that establishes the importance of T-cells in providing more durable protection against COVID-19," commented Dr.
NetScientific holds approximately 5.75% of PDS' undiluted share capital.
The full details of the announcement are set out below and can be found here:
# # #
PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamuneâ-based COVID-19 Vaccine
Versamuneâ T-cell activating platform demonstrates breadth of anti-SARS-CoV-2 immune responses in a COVID-19 vaccine
The preclinical study compared various treatment regimens in their ability to induce antibodies against SARS-CoV-2:
• the NDV vaccine alone at doses of 5μg, 10μg and 20μg,
• the NDV vaccine in combination with Versamune® at 0.2μg, 1μg and 5μg,
• and the NDV vaccine in combination with Addavax, an adjuvant well-known for its ability to induce powerful antibody responses, at 0.2μg, 1μg and 5μg.
As seen in Figure 3B of the publication, shown below, the NDV vaccine with R-DOTAP, the active ingredient in Versamune, yielded the strongest antibody responses. Figure 3C, also shown below, highlighted Versamune's ability to induce the highest levels of neutralizing antibodies even at the lowest studied antigen dose of 0.2μg. Challenge studies also demonstrated that the Versamune-containing vaccine conferred protection against SARS-CoV-2 infection.
http://www.rns-pdf.londonstockexchange.com/rns/4155J_1-2020-12-21.pdf
PDS Biotech is jointly developing PDS0203 with the Brazilian company Farmacore. PDS0203 is a second-generation Versamune-based COVID-19 vaccine: a simple subunit vaccine that utilizes a recombinant protein derived from the Spike protein of SARS-CoV-2, as opposed to an inactivated virus-based vaccine. Preclinical studies of PDS0203 have confirmed the induction of strong neutralizing antibodies, virus-specific polyfunctional CD8+ (killer) and CD4+ (helper) T-cells, and long-term memory T-cell responses.
Dr.
"The first wave of COVID-19 vaccines focused on antibody generation. However, there is a growing body of literature that establishes the importance of T-cells in providing more durable protection against COVID-19," commented Dr.
The studies detailed in Vaccine were conducted under a drug testing agreement between PDS Biotech and Icahn School of Medicine at Mount Sinai.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. The company's lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in multiple indications. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
AboutPDS0203
PDS0203 is an investigational vaccine designed for the prevention of COVID-19 being jointly developed by PDS Biotech and Farmacore. PDS0203 combines the utility of PDS Biotech's Versamune® platform with a recombinant native Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protein recognizable by our immune system (antigen). The Versamune® platform, due to its unique ability to induce both antibody and T-cell responses is being utilized to develop a next generation vaccine that may more effectively prevent COVID-19.
# # #
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Following the publication of this announcement, this inside information is now considered to be in the public domain.
For more information, please contact:
NetScientific
WH Ireland (NOMAD, Financial Adviser and Broker)
About NetScientific
NetScientific is a life sciences, technology, investment and commercialisation Group, leveraging trans-Atlantic relationships and global opportunities to deliver shareholder value.
For more information, please visit the website at www.NetScientific.net
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
